

1 **Gut-derived PPAR- $\gamma$  signaling and risk of bacterial enteric infection: insight from**  
2 **thiazolidinedione users in a US population-based study**

3 Morgan Birabaharan<sup>1\*</sup>, David C Kaelber<sup>2</sup>, Victor Nizet<sup>3-4</sup>, Amir Zarrinpar<sup>5-9\*</sup>

4 1 Division of Infectious Diseases and Global Public Health, University of California, San Diego,  
5 La Jolla, California, USA

6 2 Departments of Population and Quantitative Health Sciences, Case Western Reserve  
7 University School of Medicine, Cleveland, Ohio, USA

8 3 Division of Host-Microbe Systems and Therapeutics, Department of Pediatrics, UC San Diego  
9 School of Medicine

10 4 Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San  
11 Diego, La Jolla, California

12 5 Division of Gastroenterology, University of California, San Diego, La Jolla, CA, USA

13 6 Center for Microbiome Innovation, University of California, San Diego, La Jolla, CA, USA.

14 7 Division of Gastroenterology, Jennifer Moreno Department of Veterans Affairs Medical Center

15 8 Institute of Diabetes and Metabolic Health, University of California, San Diego, La Jolla, CA,  
16 USA

17 9 Shu Chien-Gen Lay Department of Bioengineering, University of California San Diego, La  
18 Jolla, CA, USA

19

20 \*co-Corresponding author

21 Lead Contact: Amir Zarrinpar, MD, PhD, 9500 Gilman Dr, MC 0983, University of California, San  
22 Diego, La Jolla, CA 92093-0983

23 **Conflict of Interest:** VN has served as a consultant and on the scientific advisory board for Cellics  
24 Therapeutics, I2Pure Inc, Clarametix Therapeutics, and has licensed technology from lab  
25 sponsored research with Vaxcyte, Inc. AZ is a co-founder and acting CMO of Endure  
26 Biotherapeutics. He holds equity in the company.

27 **Author Contributions:** MB conceptualized the project, designed the analysis, processed the  
28 data, and analyzed the results. DCK assisted with data acquisition. MB wrote the manuscript,  
29 DCK, VN, and AZ provided critical intellectual input. AZ supervised the study and is ultimately  
30 responsible for its content.

31 **Data Availability:** This study used population-level aggregate and deidentified data generated  
32 by the TriNetX Platform. Due to data privacy, patient-level data was not used and cannot be  
33 shared  
34

35 **Preprint:** <https://www.medrxiv.org/content/10.1101/2024.09.24.24313682v1>

36 **Abstract**

37 Background and Aims

38 The ongoing antimicrobial resistant crisis heralds the need for new therapeutics against enteric  
39 infection. In mouse models, colon epithelial peroxisome proliferator-activated receptor- $\gamma$  (PPAR-  
40  $\gamma$ ) signaling limits oxygen and nitrate luminal bioavailability, thereby preventing bacterial pathogen  
41 colonization. However, whether this mechanism operates similarly in humans remains uncertain.

42 Methods

43 To investigate, we used the cloud-based TriNetX Analytics Platform which aggregates health  
44 records from 117 million patients across 66 US healthcare organizations, to assess the risk of  
45 bacterial enteric infection among diabetic patients prescribed thiazolidinediones, a class of PPAR-  
46  $\gamma$  agonists, to other anti-diabetes medications.

47 Results

48 Among 85,117 thiazolidinedione users, we observed a 22-49% lower risk of bacterial enteric  
49 infections compared to users of other anti-diabetes medications. This reduction in risk was  
50 consistent across high-risk individuals, regardless of sex or age. Similar results were replicated  
51 in high-risk patients when thiazolidinedione users were directly compared to those on DPP-4  
52 inhibitors.

53 Conclusion

54 These findings support the potential protective role of PPAR- $\gamma$  signaling against bacterial enteric  
55 infection and call for further clinical investigation.

56 **Keywords:** gut microbiota; PPAR gamma; bacterial enteric infection; antimicrobial resistance;  
57 thiazolidinediones

58

59

## 60 **Introduction**

61 The body's primary defense against bacterial enteric infection relies heavily on the abundant and  
62 diverse intestinal microbiota [1,2]. These gut commensal microbes confer protection by direct  
63 bacteria-to-bacteria interactions and activating host immune defenses—a phenomenon known as  
64 colonization resistance [1,2]. Amid the ongoing antimicrobial resistant crisis, understanding the  
65 mechanisms of colonization resistance has gained increasing importance. Identifying microbial  
66 metabolites, proteins, or host receptors involved in preventing infection can lead to new anti-  
67 infective strategies and potentially reduce the 1.6-2.1 million annual diarrheal deaths worldwide  
68 [3].

69 Recent mechanistic studies have highlighted a central role of the host nuclear hormone receptor  
70 peroxisome proliferator-activated receptor (PPAR- $\gamma$ ) in colonization resistance [4,5]. Commensal  
71 colonic microbes, predominantly obligate anaerobes, thrive in an oxygen- and nitrate- deprived  
72 environment, limiting the expansion of facultative anaerobic organisms such as *Salmonella* and  
73 Enterobacteriaceae. These microbes maintain the low-oxygen environment by producing  
74 metabolites such as butyrate, which activates PPAR- $\gamma$  in colonocytes [4,5]. This activation  
75 enhances oxygen consumption by the host, sustaining the protective anaerobic state. In mouse  
76 models, depletion of PPAR- $\gamma$  signaling—triggered by antibiotics or a high-fat diet—has been  
77 associated with increased bacterial pathogenesis, aligning with well-known patient risk factors [4-  
78 9]. Pharmacological PPAR- $\gamma$  agonists have also shown promising results in restoring this  
79 protective effect [10]. However, it remains unclear whether PPAR- $\gamma$  offers similar protection  
80 against enteric infection in humans.

81 Thiazolidinediones, a class of PPAR- $\gamma$  agonists, are commonly used in the management of type  
82 2 diabetes mellitus (T2DM) [11,12]. Assessing the risk of bacterial enteric infection in  
83 thiazolidinediones users compared to those receiving other anti-diabetes medications could  
84 provide insights into the viability of targeting PPAR- $\gamma$  for anti-infective purposes. In this study, we

85 conducted a population-based analysis in the US to assess the risk of bacterial enteric infection  
86 in T2DM patients using thiazolidinediones anti-diabetes medications.

87

## 88 **Methods**

### 89 **Data**

90 We used the cloud-based TriNetX Analytics Platform, US Collaborative Network, to obtain web-  
91 based real-time secure access to fully deidentified electronic health records of 117 million patients  
92 from 66 health care organizations, representing 27% of the US population from all 50 states. Both  
93 inpatient and outpatient settings mostly from large academic medical institutions in the US, as  
94 well as persons from diverse geographic, age, race and ethnicity, income, and insurance groups  
95 are represented. The geographic distribution of patients from the TriNetX platform is 25% in the  
96 Northeast, 17% in the Midwest, 41% in the South, and 12% in the West, with 5% unknown.

97

### 98 **Ethics Statement**

99 The TriNetX platform aggregates and HIPAA de-identifies data contributed from the electronic  
100 health records of participating healthcare organizations. The TriNetX platform also only reports  
101 population-level results (no access to individual patient data) and uses statistical blurring,  
102 reporting all population-level counts between 1 and 10 as 10. Because this study used only  
103 deidentified patient records, it was exempted from review by the MetroHealth System Institutional  
104 Review Board.

105

### 106 **Study populations**

107 Risk for bacterial enteric infection can often be based on factors that are not well captured by  
108 electronic medical records, including consumption of undercooked meat or international travel,  
109 and may be a rare occurrence in those without risk factors present. Therefore, the outcome of

110 bacterial enteric infection after prescription of thiazolidinedione or other anti-diabetes medication  
111 was determined among a “low-risk” and “high-risk” cohort. Low-risk for bacterial enteric infection  
112 was defined as no prior history of bacterial enteric infection. High-risk was defined as persons  
113 with a previous diagnosis of bacterial enteric infection, suggesting risk factors for disease such  
114 as altered gut microbiota, behavioral and environmental factors, or predisposing chronic diseases  
115 are present [13-16].

116

117 The study was designed for a 5-year recruitment date, from 3 January 2017 to an end date of 3  
118 January 2022. The start date was chosen to help include the approval of semaglutide for T2DM  
119 management (FDA approved Dec 2017) and the end date was chosen to minimize overlap of  
120 GLP1 agonist approval for weight loss in those without diabetes (FDA approved June 2021). The  
121 index events for each were time of anti-diabetes medication prescription

122

### 123 **The study population at low-risk for bacterial enteric infection**

124 Two thiazolidinediones are available in the United States, pioglitazone and rosiglitazone.  
125 Accordingly, all persons  $\geq 18$  years of age between January 2017 and January 2022 who within 1  
126 month after a medical encounter for the diagnosis of type 2 diabetes mellitus were prescribed  
127 thiazolidinediones (pioglitazone or rosiglitazone) or non-thiazolidinediones anti-diabetes  
128 medications (Glucagon-like peptide-1 (GLP-1) analogues, insulin, metformin, sulfonylureas, alpha  
129 glucosidase inhibitors, DPP-4 inhibitors, SGLT2 inhibitors), and had no prior history of bacterial  
130 enteric infection before index event (prescription of anti-diabetes medication) were included. The  
131 study population was then divided into two cohorts: (1) thiazolidinedione-users at low risk and (2)  
132 non-thiazolidinedione users at low risk. Troglitazone users were excluded from the study as the  
133 medication is not available in the US due to its hepatotoxicity. In the non-thiazolidinedione cohort,  
134 persons with thiazolidinedione prescription were excluded from the non-thiazolidinedione cohort.

135

## 136 **The study population at high-risk for bacterial enteric infection**

137 Two thiazolidinediones are available in the United States, pioglitazone and rosiglitazone.  
138 Accordingly, all persons  $\geq 18$  years of age between January 2017 and January 2022 who within 1  
139 month after a medical encounter for the diagnosis of type 2 diabetes mellitus were prescribed  
140 thiazolidinediones (pioglitazone or rosiglitazone) or non-thiazolidinediones anti-diabetes  
141 medications, and had prior history of bacterial enteric infection before index event (prescription of  
142 anti-diabetes medication) were included. The study population was then divided into two cohorts:  
143 (1) thiazolidinedione-users at high risk and (2) non-thiazolidinedione users at high risk.  
144 Troglitazone users were excluded from the study as the medication is not available in the US due  
145 to its hepatotoxicity. In the non-thiazolidinedione cohort, persons with thiazolidinedione prescription  
146 were excluded from the non-thiazolidinedione cohort.

147

## 148 **Statistical analysis**

149 For each study cohort, the thiazolidinedione users and non-thiazolidinedione users were  
150 propensity score matched (1:1 using nearest neighbor greedy matching with a caliper of 0.25  
151 times the standard deviation) on covariates that are potential risk factors for bacterial enteric  
152 infection including diabetes severity, such as age, sex, race, ethnicity, overweight and obesity,  
153 lifestyle problems, ischemic heart disease, liver disease, kidney disease, lung disease,  
154 hypertension, hyperlipidemia, cerebrovascular disease, atherosclerosis, other peripheral vascular  
155 disease, tobacco use, alcohol use, human immunodeficiency virus (HIV), organ transplant, use  
156 of immunosuppressants, use of chemotherapeutics, and Hemoglobin A1C levels.

157

158 The outcome bacterial enteric infection that occurred in the 6-month time window after the index  
159 event (prescription of medication) were compared between the matched medication groups. The  
160 status of bacterial enteric infection was defined by ICD-10 A00-A05 (A00: Cholera, A01: Typhoid  
161 and paratyphoid fevers, A02: Other salmonella infections, A03: Shigellosis, A04: Other bacterial

162 intestinal infections, A05: Other bacterial foodborne intoxications, not elsewhere classified). As  
163 counts of bacterial enteric infection were low in the cohort, risk for an individual bacterial species  
164 (i.e. *Salmonella* sp, *Enterohemorrhagic E coli*) precluded statistical analysis (most counts were  
165 less than 10, therefore were rounded to 10 by TriNetX) and was not performed. Only a composite  
166 outcome was investigated.

167  
168 Several subgroup analyses were performed to assess the robustness of our results and possible  
169 bias. First, outcomes were examined when stratified by sex and age. Second, given diabetes  
170 medications are often prescribed in combination, it was necessary to evaluate whether other  
171 medications commonly administered alongside thiazolidinediones could confound observed  
172 effects. However, thiazolidinediones are rarely used for the management of T2DM because of  
173 weight gain, pedal edema, and heart failure exacerbation, leading to their classification as a third  
174 line option. Accordingly, thiazolidinediones were compared with another third-line anti-diabetes  
175 medication, dipeptidyl peptidase-4 inhibitors (DPP-4) inhibitors. Age and sex stratified analysis  
176 were not performed between thiazolidinediones and DPP-4 inhibitors as subgroups often had less  
177 than 10 persons with the desired outcome. TriNetX to maintain deidentification does not provide  
178 actual counts when below 10, which precludes accurate statistical analysis. All statistical analysis  
179 were performed with the TriNetX Advanced Analytics Platform. The TriNetX platform calculates  
180 RRs and associated confidence interval (CI) using R's Survival package, version 3.2-3, with  
181 proportional hazard assumption tested using the generalized Schoenfeld approach. Statistical  
182 significance was set a 2-sided P value of <0.05.

183  
184 **Results:**

185  
186 **Association of thiazolidinedione with risk of bacterial enteric infection in patients at low**  
187 **risk**

188  
189 The study population consisted of 85,917 and 2,154,426 persons with T2DM who between  
190 1/2017-1/2022 were prescribed thiazolidinedione or non-thiazolidinedione anti-diabetes

191 medications, respectively, and had no prior history of bacterial enteric infection. Persons on  
192 thiazolidinediones compared to non-thiazolidinedione were more likely to be older, male, white,  
193 and had higher prevalence of overweight and obesity, chronic kidney disease, and Hgb A1C levels  
194 greater than 9 (**Table 1**).

195  
196 After 1:1 propensity matching, demographic and clinical characteristics were balanced (85,916 in  
197 each cohort, 63.2 years of age, 42.9% Female, 12.8% Black, 67.7% White, 14.3% Hispanic)  
198 (**Table 1**). Matched cohorts were followed for 6 months after the index event. Compared to anti-  
199 diabetes non-thiazolidinedione medications, thiazolidinedione was associated with a lower risk of  
200 incident bacterial enteric infection among those at low-risk (0.03% vs 0.06%; RR 0.51, 95% CI  
201 0.32, 0.82). An association of lower risk for bacterial enteric infection was observed across age  
202 and sex, however only among those >65 years were findings statistically significant (0.02% vs  
203 0.05%; RR 0.44, 95% CI 0.23,0.88) (**Figure 1**).

204  
205 **Association of thiazolidinedione with risk of bacterial enteric infection in patients at high**  
206 **risk**

207  
208 The study population consisted of 1,975 and 57,963 persons with T2DM who between 1/2017-  
209 1/2022 were prescribed thiazolidinedione or non-thiazolidinedione anti-diabetes medications,  
210 respectively, and had prior history of bacterial enteric infection. Persons on thiazolidinediones  
211 were more likely to be Hispanic and White, and had higher prevalence of overweight and obesity,  
212 hypertension, hyperlipidemia, and Hb1C levels greater than 9.

213  
214 After 1:1 propensity matching, demographic and clinical characteristics were balanced (1,974 in  
215 each cohort, 63.0 years of age, 44.1% Female, 16.9% Black, 65.4% White, 20.8% Hispanic)  
216 (**Table 1**). Matched cohorts were followed for 6 months after the index event. Compared to anti-  
217 diabetes non-thiazolidinedione medications, thiazolidinedione was associated with a lower risk of  
218 incident bacterial enteric infection among those at high risk (17.6% vs 22.5%; RR 0.78, 95% CI



219 0.69,0.88). An association of lower risk for bacterial enteric infection was observed across all sex  
220 and age subgroups (**Figure 2**).

221  
222 **Association of thiazolidinedione compared to DPP-4 inhibitors with risk of bacterial enteric**  
223 **infection in patients at low and high risk (sensitivity analysis)**  
224

225 In the matched cohorts, thiazolidinedione use compared to those on DPP-4 inhibitors in patients  
226 with T2DM was associated with a lower risk of bacterial enteric infection in those at high-risk (RR  
227 0.82, 95% CI 0.72,0.93) and not those at low-risk (RR 0.96, 95% CI 0.56, 1.65) (**Figure 3**).

228

229

230 **Discussion**

231 Our analysis identified a significant association between thiazolidinedione use and a reduced risk  
232 of bacterial enteric infections in T2DM patients, consistent with findings from animal models. This  
233 protective effect was observed in both low- and high-risk populations, with notable reductions in  
234 infection across various age and sex subgroups, particularly in high-risk individuals with a history  
235 of prior infections. The reduced risk seen when comparing thiazolidinediones to third-line diabetes  
236 medications (DPP-4 inhibitors) further supports the hypothesis that modulating PPAR- $\gamma$  signaling  
237 mitigate bacterial enteric infections, especially in high-risk situations—for example, protracted  
238 antibiotic use during hospitalization, international travel to high incidence locales, or outbreaks in  
239 nursing homes and chronic care facilities.

240

241 Thiazolidinediones are typically used as a third-line medications when other anti-diabetes  
242 medications have proven ineffective or when insurance limitations restrict alternative options [12].  
243 Consequently, thiazolidinedione users often represent a population with more severe or poorly  
244 controlled diabetes, characterized by frequent healthcare encounters and lower socioeconomic  
245 status [17-18]. These factors are associated with an increased risk of bacterial enteric infection,

246 suggesting the protective effect of thiazolidinediones may be greater than what this analysis  
247 indicates [19-21].

248

249 Repurposing thiazolidinediones is not a novel concept. Initially, PPAR- $\gamma$  was believed to primarily  
250 function on adipose tissue, regulating insulin resistance, which led to the development of  
251 thiazolidinediones for diabetes management [22]. However, investigators soon appreciated the  
252 abundance of PPAR- $\gamma$  in colonic epithelial cells and its involvement in colon cancer [23,24].  
253 Subsequently, PPAR- $\gamma$  signaling was shown to reduce colonic inflammation, prompting the  
254 exploration of thiazolidinediones for inflammatory bowel disease [25]. Promising results were  
255 observed in mouse models and clinical trials [25-27]. Despite these benefits, concerns over  
256 toxicities, such as weight gain, fluid retention, and heart failure, have overshadowed the benefits  
257 of thiazolidinediones. Therefore, while this study suggests thiazolidinediones may protect against  
258 bacterial enteric infection, their repurposing for this indication is likely limited by their associated  
259 risks.

260

261 Fortunately, there are alternative ways to increase PPAR- $\gamma$  signaling. For instance, mesalamine  
262 (5-ASA), a PPAR- $\gamma$  agonist widely used for treating mild to moderate ulcerative colitis, may offer  
263 a safer alternative. Studies suggest that 5-ASA prevents the expansion of colitogenic bacteria  
264 such as *Escherichia coli* [10], indicating its potential role in preventing bacterial enteric infection  
265 in high-risk individuals.

266

267 Dietary modifications may also enhance PPAR- $\gamma$  signaling. A high-fiber diet can increase butyrate  
268 levels, which, in turn, activate PPAR- $\gamma$ . However, this depends on the presence of a gut microbiota  
269 capable of butyrate production. Unsaturated fatty acids, found in dairy and meat products, are  
270 natural PPAR- $\gamma$  ligands and may also promote colonic health, although achieving sufficient

271 intraluminal concentrations *in vivo* remains controversial. Small animal studies have  
272 demonstrated possible benefits from such dietary interventions [28,29].

273

274 One hypothesis behind the protective effects of PPAR- $\gamma$  activation is its ability to maintain an  
275 anaerobic environment in the gut, which helps prevent bacterial enteric infections. However, this  
276 mechanism does not directly explain why thiazolidinediones may also protect against  
277 *Clostridioides difficile*, an obligate anaerobe. It is possible that PPAR- $\gamma$  signaling supports the  
278 growth of beneficial anaerobes such as *Clostridium scindens* or *Blautia producta*, which inhibit *C.*  
279 *difficile* through the production of secondary bile acids and lantibiotics, respectively [30,31].  
280 Further, PPAR- $\gamma$  activity in macrophages, which has been shown to ameliorate colonic  
281 inflammation, may also contribute to this protective effect. Given that thiazolidinediones are  
282 primarily absorbed in the small intestine and may not directly reach the colon, this macrophage-  
283 mediated mechanism merits further investigation [10].

284

## 285 **Limitations**

286 There are limitations that bear consideration when interpreting the results of this study. Residual  
287 confounding, particularly diabetes severity, may impact the findings. Although we controlled for  
288 factors like ischemic heart disease, peripheral vascular disease, chronic kidney disease, and  
289 HbA1C levels, fully characterizing the severity of diabetes remains a challenge. Further,  
290 medication adherence cannot be confirmed based on electronic health records. However, our  
291 inclusion of individuals with thiazolidinedione or other anti-diabetes prescriptions following a  
292 healthcare encounter for T2DM suggests active management of the disease. Limited sample  
293 sizes precluded an analysis of dose-dependent effects and we could not assess the duration of  
294 thiazolidinedione use required for a protective effect. Further, since T2DM is often managed with  
295 a combination of medications, it is possible that other medications commonly used alongside  
296 thiazolidinediones contributed to the observed protective effect. To address this, we conducted a

297 direct comparison with DPP-4 inhibitors, which showed a decreased risk of bacterial enteric  
298 infection in high-risk individuals. Lastly, the severity of enteric infections was not captured in this  
299 study, so it remains unknown whether thiazolidinediones can reduce disease severity.

300

### 301 **Conclusion**

302 Bacterial enteric infections remain a significant public health concern, with acute gastroenteritis  
303 causing an estimated 179 million outpatient visits and nearly 500,000 hospitalizations annually  
304 [32-33]. Current antimicrobial treatments are often inadequate, as antibiotics can prolong  
305 symptoms, increase bacterial shedding, and lead to recurrence [14-16]. Given the limitations of  
306 existing treatments, preserving beneficial intestinal microbes with alternative therapies that  
307 minimize collateral damage to the microbiome is a key consideration. In this context PPAR- $\gamma$   
308 agonists may offer a promising alternative.

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

## 324 References

- 325 1. Caballero-Flores G, Pickard JM, Núñez G. Microbiota-mediated colonization resistance:  
326 mechanisms and regulation. *Nat Rev Microbiol*. 2023 Jun;21(6):347-360. doi:  
327 10.1038/s41579-022-00833-7. Epub 2022 Dec 20. PMID: 36539611; PMCID:  
328 PMC10249723.
- 329 2. Buffie CG, Pamer EG. Microbiota-mediated colonization resistance against intestinal  
330 pathogens. *Nat Rev Immunol*. 2013 Nov;13(11):790-801. doi: 10.1038/nri3535. Epub  
331 2013 Oct 7. PMID: 24096337; PMCID: PMC4194195.
- 332 3. Petri WA Jr, Miller M, Binder HJ, Levine MM, Dillingham R, Guerrant RL. Enteric infections,  
333 diarrhea, and their impact on function and development. *J Clin Invest*. 2008  
334 Apr;118(4):1277-90. doi: 10.1172/JCI34005. PMID: 18382740; PMCID: PMC2276781.
- 335 4. Byndloss MX, Olsan EE, Rivera-Chávez F, Tiffany CR, Cevallos SA, Lokken KL, Torres  
336 TP, Byndloss AJ, Faber F, Gao Y, Litvak Y, Lopez CA, Xu G, Napoli E, Giulivi C, Tsois  
337 RM, Revzin A, Lebrilla CB, Bäumlér AJ. Microbiota-activated PPAR- $\gamma$  signaling inhibits  
338 dysbiotic Enterobacteriaceae expansion. *Science*. 2017 Aug 11;357(6351):570-575. doi:  
339 10.1126/science.aam9949. PMID: 28798125; PMCID: PMC5642957.
- 340 5. Litvak Y, Byndloss MX, Bäumlér AJ. Colonocyte metabolism shapes the gut microbiota.  
341 *Science*. 2018 Nov 30;362(6418):eaat9076. doi: 10.1126/science.aat9076. PMID:  
342 30498100; PMCID: PMC6296223.
- 343 6. Yoo W, Zieba JK, Foegeding NJ, Torres TP, Shelton CD, Shealy NG, Byndloss AJ,  
344 Cevallos SA, Gertz E, Tiffany CR, Thomas JD, Litvak Y, Nguyen H, Olsan EE, Bennett  
345 BJ, Rathmell JC, Major AS, Bäumlér AJ, Byndloss MX. High-fat diet-induced colonocyte  
346 dysfunction escalates microbiota-derived trimethylamine *N*-oxide. *Science*. 2021 Aug  
347 13;373(6556):813-818. doi: 10.1126/science.aba3683. PMID: 34385401; PMCID:  
348 PMC8506909.
- 349 7. Lee JY, Cevallos SA, Byndloss MX, Tiffany CR, Olsan EE, Butler BP, Young BM, Rogers  
350 AWL, Nguyen H, Kim K, Choi SW, Bae E, Lee JH, Min UG, Lee DC, Bäumlér AJ. High-  
351 Fat Diet and Antibiotics Cooperatively Impair Mitochondrial Bioenergetics to Trigger  
352 Dysbiosis that Exacerbates Pre-inflammatory Bowel Disease. *Cell Host Microbe*. 2020  
353 Aug 12;28(2):273-284.e6. doi: 10.1016/j.chom.2020.06.001. Epub 2020 Jul 14. PMID:  
354 32668218; PMCID: PMC7429289.
- 355 8. Rivera-Chávez F, Zhang LF, Faber F, Lopez CA, Byndloss MX, Olsan EE, Xu G,  
356 Velazquez EM, Lebrilla CB, Winter SE, Bäumlér AJ. Depletion of Butyrate-Producing  
357 Clostridia from the Gut Microbiota Drives an Aerobic Luminal Expansion of Salmonella.  
358 *Cell Host Microbe*. 2016 Apr 13;19(4):443-54. doi: 10.1016/j.chom.2016.03.004. PMID:  
359 27078066; PMCID: PMC4832419.
- 360 9. Shelton CD, Sing E, Mo J, Shealy NG, Yoo W, Thomas J, Fitz GN, Castro PR, Hickman  
361 TT, Torres TP, Foegeding NJ, Zieba JK, Calcutt MW, Codreanu SG, Sherrod SD, McLean  
362 JA, Peck SH, Yang F, Markham NO, Liu M, Byndloss MX. An early-life microbiota  
363 metabolite protects against obesity by regulating intestinal lipid metabolism. *Cell Host  
364 Microbe*. 2023 Oct 11;31(10):1604-1619.e10. doi: 10.1016/j.chom.2023.09.002. Epub  
365 2023 Oct 3. PMID: 37794592; PMCID: PMC10593428.
- 366 10. Cevallos SA, Lee JY, Velazquez EM, Foegeding NJ, Shelton CD, Tiffany CR, Parry BH,  
367 Stull-Lane AR, Olsan EE, Savage HP, Nguyen H, Ghanaat SS, Byndloss AJ, Agu IO,  
368 Tsois RM, Byndloss MX, Bäumlér AJ. 5-Aminosalicylic Acid Ameliorates Colitis and  
369 Checks Dysbiotic *Escherichia coli* Expansion by Activating PPAR- $\gamma$  Signaling in the  
370 Intestinal Epithelium. *mBio*. 2021 Jan 19;12(1):e03227-20. doi: 10.1128/mBio.03227-20.  
371 PMID: 33468700; PMCID: PMC7845635.

- 372 11. Yki-Järvinen H. Thiazolidinediones. *N Engl J Med*. 2004 Sep 9;351(11):1106-18. doi:  
373 10.1056/NEJMra041001. PMID: 15356308.
- 374 12. American Diabetes Association Professional Practice Committee. 9. Pharmacologic  
375 Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022.  
376 *Diabetes Care*. 2022 Jan 1;45(Suppl 1):S125-S143. doi: 10.2337/dc22-S009. PMID:  
377 34964831.
- 378 13. Shane AL, Mody RK, Crump JA, Tarr PI, Steiner TS, Kotloff K, Langley JM, Wanke C,  
379 Warren CA, Cheng AC, Cantey J, Pickering LK. 2017 Infectious Diseases Society of  
380 America Clinical Practice Guidelines for the Diagnosis and Management of Infectious  
381 Diarrhea. *Clin Infect Dis*. 2017 Nov 29;65(12):e45-e80. doi: 10.1093/cid/cix669. PMID:  
382 29053792; PMCID: PMC5850553.
- 383 14. Humphries RM, Linscott AJ. Practical Guidance for Clinical Microbiology Laboratories:  
384 Diagnosis of Bacterial Gastroenteritis. *Clin Microbiol Rev*. 2015 Jan;28(1):3-31. doi:  
385 10.1128/CMR.00073-14. PMID: 25567220; PMCID: PMC4284301.
- 386 15. Peniche AG, Savidge TC, Dann SM. Recent insights into *Clostridium difficile*  
387 pathogenesis. *Curr Opin Infect Dis*. 2013 Oct;26(5):447-53. doi:  
388 10.1097/01.qco.0000433318.82618.c6. PMID: 23982235.
- 389 16. Crump JA, Sjölund-Karlsson M, Gordon MA, Parry CM. Epidemiology, Clinical  
390 Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial  
391 Management of Invasive Salmonella Infections. *Clin Microbiol Rev*. 2015 Oct;28(4):901-  
392 37. doi: 10.1128/CMR.00002-15. PMID: 26180063; PMCID: PMC4503790.
- 393 17. Arnold SV, Inzucchi SE, Echouffo-Tcheugui JB, Tang F, Lam CSP, Sperling LS, Kosiborod  
394 M. Understanding Contemporary Use of Thiazolidinediones. *Circ Heart Fail*. 2019  
395 Jun;12(6):e005855. doi: 10.1161/CIRCHEARTFAILURE.118.005855. PMID: 31129998.
- 396 18. Qato DM, Trivedi AN, Mor V, Dore DD. Disparities in Discontinuing Rosiglitazone  
397 Following the 2007 FDA Safety Alert. *Med Care*. 2016 Apr;54(4):406-13. doi:  
398 10.1097/MLR.0000000000000502. PMID: 26978569; PMCID: PMC4807625.
- 399 19. Chang M, Groseclose SL, Zaidi AA, Braden CR. An ecological analysis of  
400 sociodemographic factors associated with the incidence of salmonellosis, shigellosis, and  
401 *E. coli* O157:H7 infections in US counties. *Epidemiol Infect*. 2009 Jun;137(6):810-20. doi:  
402 10.1017/S0950268808001477. Epub 2008 Oct 24. PMID: 18947443.
- 403 20. Thaiss CA, Levy M, Grosheva I, Zheng D, Soffer E, Blacher E, Braverman S, Tengeler  
404 AC, Barak O, Elazar M, Ben-Zeev R, Lehavi-Regev D, Katz MN, Pevsner-Fischer M,  
405 Gertler A, Halpern Z, Harmelin A, Aamar S, Serradas P, Grosfeld A, Shapiro H, Geiger B,  
406 Elinav E. Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection.  
407 *Science*. 2018 Mar 23;359(6382):1376-1383. doi: 10.1126/science.aar3318. Epub 2018  
408 Mar 8. PMID: 29519916.
- 409 21. Bobo LD, Dubberke ER. Recognition and prevention of hospital-associated enteric  
410 infections in the intensive care unit. *Crit Care Med*. 2010 Aug;38(8 Suppl):S324-34. doi:  
411 10.1097/CCM.0b013e3181e69f05. PMID: 20647790; PMCID: PMC3657464.
- 412 22. Dubuquoy L, Rousseaux C, Thuru X, Peyrin-Biroulet L, Romano O, Chavatte P,  
413 Chamailard M, Desreumaux P. PPARgamma as a new therapeutic target in inflammatory  
414 bowel diseases. *Gut*. 2006 Sep;55(9):1341-9. doi: 10.1136/gut.2006.093484. PMID:  
415 16905700; PMCID: PMC1860011.
- 416 23. Saez E, Tontonoz P, Nelson MC, Alvarez JG, Ming UT, Baird SM, Thomazy VA, Evans  
417 RM. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. *Nat*  
418 *Med*. 1998 Sep;4(9):1058-61. doi: 10.1038/2042. PMID: 9734400.
- 419 24. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden SA, Chen LB,  
420 Singer S, Fletcher C, Spiegelman BM. Differentiation and reversal of malignant changes  
421 in colon cancer through PPARgamma. *Nat Med*. 1998 Sep;4(9):1046-52. doi:  
422 10.1038/2030. PMID: 9734398.



- 423 25. Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh SA, Flanigan A, Murthy S,  
424 Lazar MA, Wu GD. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the  
425 epithelial inflammatory response. *J Clin Invest*. 1999 Aug;104(4):383-9. doi:  
426 10.1172/JCI7145. PMID: 10449430; PMCID: PMC408529.
- 427 26. Lewis JD, Lichtenstein GR, Stein RB, Deren JJ, Judge TA, Fogt F, Furth EE, Demissie  
428 EJ, Hurd LB, Su CG, Keilbaugh SA, Lazar MA, Wu GD. An open-label trial of the PPAR-  
429 gamma ligand rosiglitazone for active ulcerative colitis. *Am J Gastroenterol*. 2001  
430 Dec;96(12):3323-8. doi: 10.1111/j.1572-0241.2001.05333.x. PMID: 11774944.
- 431 27. Lewis JD, Lichtenstein GR, Deren JJ, Sands BE, Hanauer SB, Katz JA, Lashner B,  
432 Present DH, Chuai S, Ellenberg JH, Nessel L, Wu GD; Rosiglitazone for Ulcerative Colitis  
433 Study Group. Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled  
434 trial. *Gastroenterology*. 2008 Mar;134(3):688-95. doi: 10.1053/j.gastro.2007.12.012. Epub  
435 2007 Dec 7. PMID: 18325386; PMCID: PMC2276587.
- 436 28. Hontecillas R, Wannemeulher MJ, Zimmerman DR, Hutto DL, Wilson JH, Ahn DU,  
437 Bassaganya-Riera J. Nutritional regulation of porcine bacterial-induced colitis by  
438 conjugated linoleic acid. *J Nutr*. 2002 Jul;132(7):2019-27. doi: 10.1093/jn/132.7.2019.  
439 PMID: 12097686.
- 440 29. Bassaganya-Riera J, Reynolds K, Martino-Catt S, Cui Y, Hennighausen L, Gonzalez F,  
441 Rohrer J, Benninghoff AU, Hontecillas R. Activation of PPAR gamma and delta by  
442 conjugated linoleic acid mediates protection from experimental inflammatory bowel  
443 disease. *Gastroenterology*. 2004 Sep;127(3):777-91. doi: 10.1053/j.gastro.2004.06.049.  
444 PMID: 15362034.
- 445 30. Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, No D, Liu H, Kinnebrew  
446 M, Viale A, Littmann E, van den Brink MR, Jenq RR, Taur Y, Sander C, Cross JR,  
447 Toussaint NC, Xavier JB, Pamer EG. Precision microbiome reconstitution restores bile  
448 acid mediated resistance to *Clostridium difficile*. *Nature*. 2015 Jan 8;517(7533):205-8. doi:  
449 10.1038/nature13828. Epub 2014 Oct 22. PMID: 25337874; PMCID: PMC4354891.
- 450 31. Kim SG, Becattini S, Moody TU, Shliaha PV, Littmann ER, Seok R, Gjonbalaj M, Eaton V,  
451 Fontana E, Amoretti L, Wright R, Caballero S, Wang ZX, Jung HJ, Morjaria SM, Leiner IM,  
452 Qin W, Ramos RJJF, Cross JR, Narushima S, Honda K, Peled JU, Hendrickson RC, Taur  
453 Y, van den Brink MRM, Pamer EG. Microbiota-derived lantibiotic restores resistance  
454 against vancomycin-resistant *Enterococcus*. *Nature*. 2019 Aug;572(7771):665-669. doi:  
455 10.1038/s41586-019-1501-z. Epub 2019 Aug 21. PMID: 31435014; PMCID:  
456 PMC6717508.
- 457 32. Scallan E, Griffin PM, Angulo FJ, Tauxe RV, Hoekstra RM. Foodborne illness acquired in  
458 the United States--unspecified agents. *Emerg Infect Dis*. 2011 Jan;17(1):16-22. doi:  
459 10.3201/eid1701.091101p2. PMID: 21192849; PMCID: PMC3204615.
- 460 33. Kendall ME, Crim S, Fullerton K, Han PV, Cronquist AB, Shiferaw B, Ingram LA, Rounds  
461 J, Mintz ED, Mahon BE. Travel-associated enteric infections diagnosed after return to the  
462 United States, Foodborne Diseases Active Surveillance Network (FoodNet), 2004-2009.  
463 *Clin Infect Dis*. 2012 Jun;54 Suppl 5:S480-7. doi: 10.1093/cid/cis052. PMID: 22572673.  
464

465

466

467

468

469

470 **ACKNOWLEDGMENTS**

471 MB is supported by T32 AI007036. DCK is supported by the Clinical and Translational Science  
472 Collaborative of Northern Ohio which is funded by the National Center for Advancing Translational  
473 Sciences (NCATS) of the National Institutes of Health, UM1TR004528. AZ is supported by NIH  
474 R01AZ is supported by NIH R01 EB030134, R01 AI163483, U01 CA265719, and VA Merit BLR&D  
475 Award I01 BX005707. All authors receive institutional support from NIH P30 DK120515, P30  
476 DK063491, and UL1 TR001442.

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496


497

498

499



It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/) .



500

501 **Figure 1:** Risk of bacterial enteric infection in low-risk individuals (no prior history of  
502 bacterial enteric infection); BEI, Bacterial Enteric Infection

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517


518

519

520

521

522



523

524 **Figure 2:** Risk of bacterial enteric infection in high-risk individuals (prior history of bacterial enteric  
525 infection); BEI, Bacterial Enteric Infection

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540


541

542

543

544

545



546

547 **Figure 3:** Risk of bacterial enteric infection in thiazolidine users compared to DPP-4 inhibitors  
548 with T2DM in low-risk (no prior history of bacterial enteric infection) and high-risk (prior history of  
549 bacterial enteric infection); BEI, Bacterial Enteric Infection, T2DM, Type 2 Diabetes Mellitus

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570 **Table 1:** Characteristics of the thiazolidinedione cohort and the non-thiazolidinedione anti-  
571 diabetes medication cohort for the study population at low risk for bacterial enteric infection

Characteristics	Before matching			After matching		
	TZD users	Non-TZD users	Std diff	TZD users	Non-TZD users	Std diff.
Total No.	85,917	2,154,436		85,916	85,916	
Age, mean, y	63.2 ± 12.3	61.4 ± 14.5	0.13	63.2 ± 12.3	63.4 ± 12.8	0.014
Sex, %						
Male	54.9	49.0	0.117	54.9	55.5	0.013
Female	42.9	46.9	0.082	42.9	42.3	0.012
Ethnicity, %						
Hispanic/Latino	14.3	9.3	0.156	14.3	13.6	0.021
Not Hispanic/Latino	64.2	62.3	0.040	64.2	65.1	0.019
Unknown	21.5	28.4	0.161	21.5	21.3	0.005
Race,%						
African American/Black	12.8	18.0	0.144	12.8	12.8	0.001
Asian	5.1	4.4	0.034	5.1	5.1	0.001
White	67.7	59.9	0.164	67.7	68.1	0.008
American Indian or Alaska Native	0.3	0.3	0.002	0.3	0.3	0.002
Native Hawaiian or other Pacific Islander	0.4	0.6	0.033	0.4	0.3	0.007
Other Race	3.4	3.4	0.002	3.4	3.3	0.009
Unknown	10.3	13.5	0.100	10.3	10.1	0.005
Problems related to lifestyle	4.5	4.0	0.023	4.5	4.1	0.024
Tobacco Use	10.0	10.7	0.022	10.0	9.1	0.030
Alcohol Use Disorder	2.1	2.8	0.049	2.1	1.8	0.017
Comorbidities, %						
Overweight & Obesity	31.0	25.0	0.134	31.0	30.1	0.019
BMI 19.9 or less	0.3	0.5	0.027	0.3	0.3	0.008
BMI 20-29	4.8	4.0	0.042	4.8	4.4	0.019
BMI 30-39	12.3	9.2	0.100	12.3	11.9	0.013
BMI 40 or greater	7.2	6.3	0.037	7.2	7.0	0.011
Hypertension	64.0	51.6	0.254	64.0	63.5	0.011
Hyperlipidemia	48.4	35.5	0.264	48.4	47.7	0.015
Chronic respiratory disease	17.0	17.1	0.004	17.0	16.3	0.018
Liver Disease	10.2	8.6	0.057	10.2	9.5	0.025
Chronic Kidney Disease	14.0	12.6	0.040	14.0	13.2	0.023
CKD Stage 1	0.8	0.5	0.031	0.8	0.7	0.012
CKD Stage 2 (mild)	2.5	1.8	0.048	2.5	2.2	0.018
CKD Stage 3 (moderate)	12.3	9.2	0.083	9.1	8.7	0.016
CKD Stage 4 (severe)	1.9	2.2	0.016	1.9	1.8	0.011
CKD Stage 5	0.5	1.0	0.054	0.5	0.5	0.003
End stage renal disease	1.2	2.7	0.106	1.2	1.2	0.006
Ischemic heart disease	17.0	18.4	0.035	17.0	16.3	0.019
Cerebrovascular Disease	8.7	9.1	0.011	8.7	8.1	0.023
Atherosclerosis	4.5	4.1	0.001	4.5	4.1	0.020
Other peripheral vascular disease	5.7	5.2	0.022	5.7	5.1	0.026
HIV	0.6	0.5	0.012	0.6	0.5	0.009
Organ Transplant	0.9	1.6	0.060	0.9	0.9	0.006
Medications, %						
Immunosuppressants	3.2	3.5	0.017	3.2	3.0	0.012
Chemotherapy	12.4	11.4	0.030	12.4	12.0	0.014
Labs, %						
Hemoglobin A1C						
<9%	54.3	43.2	0.225	54.3	54.0	0.006

	$\geq 9\%$	30.6	16.5	0.338	30.6	30.1	0.011
572	Abbreviations: TZD; thiazolidinedione, non-TZD; non-thiazolidinedione, std diff; Standard mean difference, y; years,						
573	CKD; chronic kidney disease, HIV; Human Immunodeficiency Virus; BMI; body mass index						
574							
575							
576							
577							
578							
579							
580							
581							
582							
583							
584							
585							
586							
587							
588							
589							
590							
591							
592							
593							
594							
595							
596							
597							
598							
599							

600 **Table 2:** Characteristics of the thiazolidinedione cohort and the non-thiazolidinedione anti-  
601 diabetes medication cohort for the study population at high-risk for bacterial enteric infection

Characteristics	Before matching			After matching		
	TZD users	Non-TZD users	Std diff.	TZD users	Non-TZD users	Std diff.
Total No.	1,975	57,963		1,974	1,974	
Age, mean, y	63.0 ± 12.7	62.6 ± 14.1	0.029	63.0 ± 12.7	63.1 ± 13.3	0.007
Sex, %						
Male	44.1	43.3	0.017	44.1	42.8	0.027
Female	54.3	52.9	0.029	54.3	55.1	0.017
Ethnicity, %						
Hispanic/Latino	20.9	12.3	0.233	20.8	20.8	0.001
Not Hispanic/Latino	65.7	66.3	0.013	65.7	64.5	0.026
Unknown	13.5	21.4	0.211	13.5	14.7	0.036
Race,%						
African American/Black	16.9	20.8	0.099	16.9	16.3	0.016
Asian	4.4	4.1	0.014	4.4	4.4	<0.001
White	65.4	57.7	0.158	65.4	65.8	0.009
American Indian or Alaska Native	0.5	0.4	0.020	0.5	0.5	<0.001
Native Hawaiian or other Pacific Islander	0.6	1.0	0.053	0.6	0.5	0.007
Other Race	3.4	3.3	0.011	3.4	3.2	0.011
Unknown	9.0	12.7	0.120	9.0	9.4	0.014
Lifestyle problem	8.6	7.6	0.036	8.6	7.4	0.041
Tobacco Use	16.2	18.2	0.053	16.2	14.4	0.049
Alcohol Use Disorder	5.3	6.9	0.067	5.3	4.4	0.040
Comorbidities, %						
Overweight & Obesity	45.9	38.6	0.147	45.8	43.4	0.049
BMI 19.9 or less	1.8	2.0	0.011	1.8	1.6	0.020
BMI 20-29	8.4	8.4	0.001	8.4	7.0	0.049
BMI 30-39	17.5	15.2	0.061	17.5	16.0	0.039
BMI 40 or greater	12.7	10.5	0.067	12.6	11.6	0.031
Hypertension	79.8	71.5	0.195	79.8	77.1	0.067
Hyperlipidemia	67.4	54.7	0.263	67.4	64.9	0.051
Chronic respiratory disease	29.6	31.9	0.050	29.6	27.7	0.043
Liver Disease	24.4	21.8	0.061	24.2	22.2	0.052
Chronic Kidney Disease	28.7	32.5	0.084	28.6	27.4	0.027
CKD Stage 1	2.0	1.5	0.036	1.9	2.3	0.028
CKD Stage 2 (mild)	5.7	5.1	0.026	5.7	6.3	0.026
CKD Stage 3 (moderate)	19.3	18.2	0.029	19.3	18.2	0.027
CKD Stage 4 (severe)	5.4	8.6	0.125	5.4	5.1	0.014
CKD Stage 5	1.7	5.0	0.184	1.7	1.6	0.012
End stage renal disease	4.4	10.9	0.248	4.4	4.0	0.020
Ischemic heart disease	28.7	33.9	0.113	28.7	26.2	0.055
Cerebrovascular Disease	17.0	18.9	0.050	16.9	14.6	0.064
Atherosclerosis	10.9	12.2	0.043	10.9	9.2	0.056
Other peripheral vascular disease	11.6	12.8	0.037	11.6	10.0	0.051
HIV	1.4	1.3	0.007	1.4	1.3	0.009
Organ Transplant	3.7	8.0	0.184	3.7	4.0	0.013
Medications						
Immunosuppressants	8.2	11.7	0.116	8.2	7.0	0.044
Chemotherapy	24.8	25.6	0.020	24.8	22.7	0.049
Labs						
Hemoglobin A1C						

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

<9%	69.8	61.6	0.173	69.8	69.1	0.014
≥9%	43.0	24.5	0.400	43.0	43.2	0.003

602 Abbreviations: TZD; thiazolidinedione, non-TZD; non-thiazolidinedione, std diff; Standard mean difference, y; years,  
603 CKD; chronic kidney disease, HIV; Human Immunodeficiency Virus; BMI; body mass index

604